Quince Therapeutics (QNCX) Cash from Investing Activities (2018 - 2026)

Quince Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at $12.0 million for Q1 2026.

• In Q1 2026, Cash from Investing Activities rose 10.11% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $24.3 million (up 1.83% YoY), while the FY2025 annual figure was $23.2 million, up 6.02% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at $12.0 million, up from $8.1 million in the prior quarter.
• The five-year high for Cash from Investing Activities was $18.7 million in Q4 2022, with the low at -$20.3 million in Q2 2023.
• The 5-year median for Cash from Investing Activities is $6.0 million (2025), against an average of $4.1 million.
• The sharpest annual moves came in 2022 and 2025: Cash from Investing Activities plunged 1252.22% in 2022, then jumped 221.31% in 2025.
• Quince Therapeutics' Cash from Investing Activities stood at $18.7 million in 2022, then tumbled by 71.12% to $5.4 million in 2023, then jumped by 101.61% to $10.9 million in 2024, then dropped by 25.73% to $8.1 million in 2025, then jumped by 48.68% to $12.0 million in 2026.
• Business Quant data shows QNCX's Cash from Investing Activities at $12.0 million in Q1 2026, $8.1 million in Q4 2025, and -$1.8 million in Q3 2025.